|
More
Compensation Systems
Research Library
|
|
HighPoint Solutions
|
Sales models are evolving to meet the new challenges of today's market, and incentive compensation and measurement plans are changing as a result. As the new environment of pharma sales shifts to more specialized and consumer-centric approaches, the industry will need to adequately compensate and incentivize its sales teams.
|
|
|
Quintiles Transnational
|
In its response to the cacophony of demands for cost-effective, innovative medicines, the biopharmaceutical industry has a unique chance to influence the U.S. health care landscape. The traditional model of pharmaceutical R&D in which a steady stream of broadly indicated blockbusters gave market-based rewards is a rapidly fading memory. While products are becoming more targeted to smaller patient ...
|
|
|
Aptuit
|
Pharmaceutical and biotech companies of all sizes are increasingly turning to third parties to execute some or all of their clinical supply activities. There is a need for these companies to control and track these activities in their information systems.
This article addresses the various methods in which the activities of third-party supply contractors and IVRS (Interactive Voice Response ...
|
|
|
TUV SUD America Inc.
|
The voluntary certification of a quality management system, specifically for medical devices, to ISO 13485 proves advantageous, and in many cases essential, for medical companies which export their products in the global market.
In the European Union, the fulfillment of EU Directives (e.g., Active Implantable Medical Device Directive, Medical Device Directive and In Vitro Diagnostic Directive) ...
|
|
|
BatchMaster Software
|
The purpose of this white paper is to document and summarize the current status of the regulatory requirements set forth by different agencies like FDA (in US), ICH (in Europe), and that of Japan and China. In the first section of the paper we will provide the background information on the role of FDA, the regulatory agency in the USA, and the current state of cGMP “risk based approach” enforced ...
|
|
|
|
